
    
      We recruited the patients who were pathologically confirmed with esophageal squamous cell
      carcinoma from the Oct 2014. The the patients was divided into two groups. Group 1:
      Capecitabine + chemoradiation, radiation at the end of the stop using capecitabine. Group 2:
      Capecitabine + chemoradiation, at the end of the radiotherapy with capecitabine consolidating
      treatment for 5 weeks.
    
  